| Assay ID | Title | Year | Journal | Article |
|---|
| AID1346987 | P-glycoprotein substrates identified in KB-8-5-11 adenocarcinoma cell line, qHTS therapeutic library screen | 2019 | Molecular pharmacology, 11, Volume: 96, Issue:5
| A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein. |
| AID1296008 | Cytotoxic Profiling of Annotated Libraries Using Quantitative High-Throughput Screening | 2020 | SLAS discovery : advancing life sciences R & D, 01, Volume: 25, Issue:1
| Cytotoxic Profiling of Annotated and Diverse Chemical Libraries Using Quantitative High-Throughput Screening. |
| AID1347086 | qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lymphocytic Choriomeningitis Arenaviruses (LCMV): LCMV Primary Screen - GLuc reporter signal | 2020 | Antiviral research, 01, Volume: 173 | A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity. |
| AID1347096 | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for U-2 OS cells | 2018 | Oncotarget, Jan-12, Volume: 9, Issue:4
| Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing. |
| AID1347103 | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for OHS-50 cells | 2018 | Oncotarget, Jan-12, Volume: 9, Issue:4
| Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing. |
| AID1347091 | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SJ-GBM2 cells | 2018 | Oncotarget, Jan-12, Volume: 9, Issue:4
| Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing. |
| AID1347100 | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for LAN-5 cells | 2018 | Oncotarget, Jan-12, Volume: 9, Issue:4
| Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing. |
| AID1347107 | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh30 cells | 2018 | Oncotarget, Jan-12, Volume: 9, Issue:4
| Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing. |
| AID1347083 | qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: Viability assay - alamar blue signal for LASV Primary Screen | 2020 | Antiviral research, 01, Volume: 173 | A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity. |
| AID1347099 | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for NB1643 cells | 2018 | Oncotarget, Jan-12, Volume: 9, Issue:4
| Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing. |
| AID1347104 | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for RD cells | 2018 | Oncotarget, Jan-12, Volume: 9, Issue:4
| Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing. |
| AID1347095 | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for NB-EBc1 cells | 2018 | Oncotarget, Jan-12, Volume: 9, Issue:4
| Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing. |
| AID1347090 | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for DAOY cells | 2018 | Oncotarget, Jan-12, Volume: 9, Issue:4
| Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing. |
| AID1347098 | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SK-N-SH cells | 2018 | Oncotarget, Jan-12, Volume: 9, Issue:4
| Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing. |
| AID1347411 | qHTS to identify inhibitors of the type 1 interferon - major histocompatibility complex class I in skeletal muscle: primary screen against the NCATS Mechanism Interrogation Plate v5.0 (MIPE) Libary | 2020 | ACS chemical biology, 07-17, Volume: 15, Issue:7
| High-Throughput Screening to Identify Inhibitors of the Type I Interferon-Major Histocompatibility Complex Class I Pathway in Skeletal Muscle. |
| AID1347094 | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for BT-37 cells | 2018 | Oncotarget, Jan-12, Volume: 9, Issue:4
| Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing. |
| AID1745845 | Primary qHTS for Inhibitors of ATXN expression | | | |
| AID1347105 | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for MG 63 (6-TG R) cells | 2018 | Oncotarget, Jan-12, Volume: 9, Issue:4
| Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing. |
| AID1347093 | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SK-N-MC cells | 2018 | Oncotarget, Jan-12, Volume: 9, Issue:4
| Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing. |
| AID1347092 | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for A673 cells | 2018 | Oncotarget, Jan-12, Volume: 9, Issue:4
| Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing. |
| AID1508630 | Primary qHTS for small molecule stabilizers of the endoplasmic reticulum resident proteome: Secreted ER Calcium Modulated Protein (SERCaMP) assay | 2021 | Cell reports, 04-27, Volume: 35, Issue:4
| A target-agnostic screen identifies approved drugs to stabilize the endoplasmic reticulum-resident proteome. |
| AID1347082 | qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: LASV Primary Screen - GLuc reporter signal | 2020 | Antiviral research, 01, Volume: 173 | A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity. |
| AID1347097 | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Saos-2 cells | 2018 | Oncotarget, Jan-12, Volume: 9, Issue:4
| Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing. |
| AID1347101 | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for BT-12 cells | 2018 | Oncotarget, Jan-12, Volume: 9, Issue:4
| Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing. |
| AID1347089 | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for TC32 cells | 2018 | Oncotarget, Jan-12, Volume: 9, Issue:4
| Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing. |
| AID1347106 | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for control Hh wild type fibroblast cells | 2018 | Oncotarget, Jan-12, Volume: 9, Issue:4
| Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing. |
| AID1347154 | Primary screen GU AMC qHTS for Zika virus inhibitors | 2020 | Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
| Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors. |
| AID1346986 | P-glycoprotein substrates identified in KB-3-1 adenocarcinoma cell line, qHTS therapeutic library screen | 2019 | Molecular pharmacology, 11, Volume: 96, Issue:5
| A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein. |
| AID1347102 | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh18 cells | 2018 | Oncotarget, Jan-12, Volume: 9, Issue:4
| Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing. |
| AID1347108 | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh41 cells | 2018 | Oncotarget, Jan-12, Volume: 9, Issue:4
| Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing. |
| AID1767177 | Antiproliferative activity against human MGC-803 cells | 2021 | European journal of medicinal chemistry, Oct-05, Volume: 221 | Structure-based discovery of potent and selective small-molecule inhibitors targeting signal transducer and activator of transcription 3 (STAT3). |
| AID1717301 | Cytotoxicity against human A-375 cells assessed as inhibition of cell proliferation measured after 48 hrs by MTS assay | 2020 | European journal of medicinal chemistry, Jan-15, Volume: 186 | NO-releasing STAT3 inhibitors suppress BRAF-mutant melanoma growth. |
| AID1767176 | Antiproliferative activity against human MDA-MB-231 cells | 2021 | European journal of medicinal chemistry, Oct-05, Volume: 221 | Structure-based discovery of potent and selective small-molecule inhibitors targeting signal transducer and activator of transcription 3 (STAT3). |
| AID1717300 | Cytotoxicity against human MCF-10A cells assessed as inhibition of cell proliferation by MTS assay | 2020 | European journal of medicinal chemistry, Jan-15, Volume: 186 | NO-releasing STAT3 inhibitors suppress BRAF-mutant melanoma growth. |
| AID580781 | Inhibition of STAT3 in human MDA-MB-468 cells assessed as reduction in survivin expression at 20 uM by Western blotting | 2010 | ACS medicinal chemistry letters, Nov-11, Volume: 1, Issue:8
| Identification of a New Series of STAT3 Inhibitors by Virtual Screening. |
| AID580771 | Inhibition of STAT3 dimerization transfected in HEK293 cells at 50 uM after 24 hrs followed by 1 hr stimulation with 50 ng/ml IL-6 by FRET assay | 2010 | ACS medicinal chemistry letters, Nov-11, Volume: 1, Issue:8
| Identification of a New Series of STAT3 Inhibitors by Virtual Screening. |
| AID580914 | Induction of apoptosis in human MDA-MB-453 cells assessed as increase in caspase3/7 activity at 1-100 uM by fluorescence assay | 2010 | ACS medicinal chemistry letters, Nov-11, Volume: 1, Issue:8
| Identification of a New Series of STAT3 Inhibitors by Virtual Screening. |
| AID580788 | Toxicity in BALB/cA-v/v nude mouse assessed as increase in body weight relative to control | 2010 | ACS medicinal chemistry letters, Nov-11, Volume: 1, Issue:8
| Identification of a New Series of STAT3 Inhibitors by Virtual Screening. |
| AID1717299 | Cytotoxicity against HFF assessed as inhibition of cell proliferation by MTS assay | 2020 | European journal of medicinal chemistry, Jan-15, Volume: 186 | NO-releasing STAT3 inhibitors suppress BRAF-mutant melanoma growth. |
| AID580913 | Induction of apoptosis in human MDA-MB-468 cells assessed as increase in caspase3/7 activity at 1-100 uM by fluorescence assay | 2010 | ACS medicinal chemistry letters, Nov-11, Volume: 1, Issue:8
| Identification of a New Series of STAT3 Inhibitors by Virtual Screening. |
| AID580777 | Inhibition of STAT3 in human MDA-MB-468 cells assessed as reduction in cyclin D1 expression at 10 uM by Western blotting | 2010 | ACS medicinal chemistry letters, Nov-11, Volume: 1, Issue:8
| Identification of a New Series of STAT3 Inhibitors by Virtual Screening. |
| AID580778 | Inhibition of STAT3 in human MDA-MB-468 cells assessed as reduction in cyclin D1 expression at 20 uM by Western blotting | 2010 | ACS medicinal chemistry letters, Nov-11, Volume: 1, Issue:8
| Identification of a New Series of STAT3 Inhibitors by Virtual Screening. |
| AID1767291 | Antitumor activity against patient-derived breast cancer cells xenografted in NOD/SCID mouse assessed as tumor growth inhibition at 15 mg/kg, iv administered once daily for 20 days | 2021 | European journal of medicinal chemistry, Oct-05, Volume: 221 | Structure-based discovery of potent and selective small-molecule inhibitors targeting signal transducer and activator of transcription 3 (STAT3). |
| AID580783 | Inhibition of STAT3 DNA binding activity in IL-6 stimulated human MDA-MB-468 cells at 50 uM by transcription factor ELISA | 2010 | ACS medicinal chemistry letters, Nov-11, Volume: 1, Issue:8
| Identification of a New Series of STAT3 Inhibitors by Virtual Screening. |
| AID580787 | Antitumor activity against human SCC-3 cells xenografted in BALB/cA-v/v nude mouse assessed as decrease in tumor volume at 160 mg/kg, po QD for 4 days measured on 4th day relative to control | 2010 | ACS medicinal chemistry letters, Nov-11, Volume: 1, Issue:8
| Identification of a New Series of STAT3 Inhibitors by Virtual Screening. |
| AID580772 | Inhibition of STAT3 dimerization transfected in HEK293 cells at 100 uM after 24 hrs followed by 1 hr stimulation with 50 ng/ml IL-6 by FRET assay | 2010 | ACS medicinal chemistry letters, Nov-11, Volume: 1, Issue:8
| Identification of a New Series of STAT3 Inhibitors by Virtual Screening. |
| AID580775 | Inhibition of STAT3 in human MDA-MB-468 cells assessed as reduction in c-myc expression at 20 uM by Western blotting | 2010 | ACS medicinal chemistry letters, Nov-11, Volume: 1, Issue:8
| Identification of a New Series of STAT3 Inhibitors by Virtual Screening. |
| AID580790 | Plasma concentration in CD1(ICR) mouse at 160 mg/kg, po after 8 hrs by LC-MS analysis | 2010 | ACS medicinal chemistry letters, Nov-11, Volume: 1, Issue:8
| Identification of a New Series of STAT3 Inhibitors by Virtual Screening. |
| AID580769 | Inhibition of STAT3 transcriptional activity in human HeLa cells at 100 uM by luciferase reporter gene assay | 2010 | ACS medicinal chemistry letters, Nov-11, Volume: 1, Issue:8
| Identification of a New Series of STAT3 Inhibitors by Virtual Screening. |
| AID580770 | Inhibition of STAT3 transcriptional activity in human HeLa cells by luciferase reporter gene assay | 2010 | ACS medicinal chemistry letters, Nov-11, Volume: 1, Issue:8
| Identification of a New Series of STAT3 Inhibitors by Virtual Screening. |
| AID580784 | Inhibition of STAT1 DNA binding activity in IL-6 stimulated human MDA-MB-468 cells at 50 uM by transcription factor ELISA | 2010 | ACS medicinal chemistry letters, Nov-11, Volume: 1, Issue:8
| Identification of a New Series of STAT3 Inhibitors by Virtual Screening. |
| AID1767178 | Antiproliferative activity against human A549 cells | 2021 | European journal of medicinal chemistry, Oct-05, Volume: 221 | Structure-based discovery of potent and selective small-molecule inhibitors targeting signal transducer and activator of transcription 3 (STAT3). |
| AID580789 | Toxicity in BALB/cA-v/v nude mouse assessed as mortality | 2010 | ACS medicinal chemistry letters, Nov-11, Volume: 1, Issue:8
| Identification of a New Series of STAT3 Inhibitors by Virtual Screening. |
| AID580780 | Inhibition of STAT3 in human MDA-MB-468 cells assessed as reduction in survivin expression at 10 uM by Western blotting | 2010 | ACS medicinal chemistry letters, Nov-11, Volume: 1, Issue:8
| Identification of a New Series of STAT3 Inhibitors by Virtual Screening. |
| AID580776 | Inhibition of STAT3 in human MDA-MB-468 cells assessed as reduction in c-myc expression at 50 uM by Western blotting | 2010 | ACS medicinal chemistry letters, Nov-11, Volume: 1, Issue:8
| Identification of a New Series of STAT3 Inhibitors by Virtual Screening. |
| AID580785 | Inhibition of STAT5a DNA binding activity in IL-6 stimulated human MDA-MB-468 cells at 50 uM by transcription factor ELISA | 2010 | ACS medicinal chemistry letters, Nov-11, Volume: 1, Issue:8
| Identification of a New Series of STAT3 Inhibitors by Virtual Screening. |
| AID580786 | Inhibition of STAT5b DNA binding activity in IL-6 stimulated human MDA-MB-468 cells at 50 uM by transcription factor ELISA | 2010 | ACS medicinal chemistry letters, Nov-11, Volume: 1, Issue:8
| Identification of a New Series of STAT3 Inhibitors by Virtual Screening. |
| AID580773 | Inhibition of STAT3 in IL-6 stimulated human MDA-MB-468 cells assessed as reduction in amplification of c-myc promoter by CHIP assay | 2010 | ACS medicinal chemistry letters, Nov-11, Volume: 1, Issue:8
| Identification of a New Series of STAT3 Inhibitors by Virtual Screening. |
| AID580774 | Inhibition of STAT3 in human MDA-MB-468 cells assessed as reduction in c-myc expression at 10 uM by Western blotting | 2010 | ACS medicinal chemistry letters, Nov-11, Volume: 1, Issue:8
| Identification of a New Series of STAT3 Inhibitors by Virtual Screening. |
| AID580782 | Inhibition of STAT3 in human MDA-MB-468 cells assessed as reduction in survivin expression at 50 uM by Western blotting | 2010 | ACS medicinal chemistry letters, Nov-11, Volume: 1, Issue:8
| Identification of a New Series of STAT3 Inhibitors by Virtual Screening. |
| AID580779 | Inhibition of STAT3 in human MDA-MB-468 cells assessed as reduction in cyclin D1 expression at 50 uM by Western blotting | 2010 | ACS medicinal chemistry letters, Nov-11, Volume: 1, Issue:8
| Identification of a New Series of STAT3 Inhibitors by Virtual Screening. |
| AID1767301 | Toxicity in NOD/SCID mouse xenografted with patient-derived breast cancer cells assessed as change in body weight at 5 to 15 mg/kg, iv administered once daily for 20 days | 2021 | European journal of medicinal chemistry, Oct-05, Volume: 221 | Structure-based discovery of potent and selective small-molecule inhibitors targeting signal transducer and activator of transcription 3 (STAT3). |
| AID1159607 | Screen for inhibitors of RMI FANCM (MM2) intereaction | 2016 | Journal of biomolecular screening, Jul, Volume: 21, Issue:6
| A High-Throughput Screening Strategy to Identify Protein-Protein Interaction Inhibitors That Block the Fanconi Anemia DNA Repair Pathway. |
| [information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023] |